About US
Contact us
>>Back
Pfizer aims to jump start stalled arthritis-pain drugs
- Publisher：
- Publication：2012/3/13
Pfizer ($PFE) is making a pitch for reviving the anti-nerve growth factor drug it shelved two years ago on safety concerns. The arthritis pain treatment is one of several anti-NGF drugs, so if FDA allows new studies in osteoarthritis patients, then potential rivals from Johnson & Johnson ($JNJ), AstraZeneca ($AZN), and Regeneron ($REGN) could find new life, too.